<p>PBMC freshly isolated from whole blood of 135 HD patients were incubated 24hrs in presence of nHBHA (2 µg/ml) with 5 ng/ml IL-7, or 96hrs in presence of PPD (4 µg/ml) before measuring the corresponding IFN-γ concentrations released in the supernatant. The squares represent the IFN-γ concentrations (pg/ml) in response to PPD and nHBHA in QFT positive patients (Panel A, n = 45) and in QFT negative patients (Panel B, n = 90). Each square symbolizes a single patient, black and open squares representing patients originated from high and low incidence TB countries, respectively. Dotted lines indicate the positivity cut-off for each test. Percentages represent the proportion of results within the indicated quadrant among the total number of pat...
<p>IGRAs: Interferon-γ release assays; QFT-GIT: QuantiFERON®-TB Gold In-Tube; n/N: positive cases/ca...
<p>(A) CD4<sup>+</sup> and CD8<sup>+</sup>T cell numbers are significant decreased in the peripheral...
<p>(A-B) Comparison of (A) the total magnitudes (<i>y axis</i>) of <i>ex vivo</i> ELISPOT IFN-γ T-ce...
<p>PBMC freshly isolated from whole blood of 135 HD patients were incubated 24 hrs in presence of nH...
<p>The data are presented as median and interquartile range or as number (%).</p><p>IGRA, interferon...
<p>The effect of IL-7 on the IFN-γ secretion was analysed for 7 LTBI (panel A) and 7 control subject...
*<p>Per patient P-values are shown for each IGRA for comparisons between 0 and 2 months.</p
IFN-ℽ release (a) and Pearson’s correlation values (b) between IFN-ℽ released against mixtures of th...
<p>IFNγ-response to different <i>Mtb</i>-antigens was evaluated by short-term stimulation of whole b...
<p>Blood samples were collected from LTBI subjects during the first two years (recent) or after two ...
<p>Blood from patients with active VL (VL, n = 23), after 17 days (TOC, n = 16), 3 months (n = 20) o...
Recently, the American Thoracic Society/Infectious Diseases Society of America/Centers for Disease C...
<p>(A) Proportion of activated circulating HLA-DR+CR38+ CD4+ T cells. (B) Proportion of activated ci...
<p>The samples were collected from SIT-untreated AR patients (open circles), SIT-treated AR patients...
<p>(A) Comparison of the ability of healthy donors and CHB patients to produce IFN-α. PBMCs (2×10<su...
<p>IGRAs: Interferon-γ release assays; QFT-GIT: QuantiFERON®-TB Gold In-Tube; n/N: positive cases/ca...
<p>(A) CD4<sup>+</sup> and CD8<sup>+</sup>T cell numbers are significant decreased in the peripheral...
<p>(A-B) Comparison of (A) the total magnitudes (<i>y axis</i>) of <i>ex vivo</i> ELISPOT IFN-γ T-ce...
<p>PBMC freshly isolated from whole blood of 135 HD patients were incubated 24 hrs in presence of nH...
<p>The data are presented as median and interquartile range or as number (%).</p><p>IGRA, interferon...
<p>The effect of IL-7 on the IFN-γ secretion was analysed for 7 LTBI (panel A) and 7 control subject...
*<p>Per patient P-values are shown for each IGRA for comparisons between 0 and 2 months.</p
IFN-ℽ release (a) and Pearson’s correlation values (b) between IFN-ℽ released against mixtures of th...
<p>IFNγ-response to different <i>Mtb</i>-antigens was evaluated by short-term stimulation of whole b...
<p>Blood samples were collected from LTBI subjects during the first two years (recent) or after two ...
<p>Blood from patients with active VL (VL, n = 23), after 17 days (TOC, n = 16), 3 months (n = 20) o...
Recently, the American Thoracic Society/Infectious Diseases Society of America/Centers for Disease C...
<p>(A) Proportion of activated circulating HLA-DR+CR38+ CD4+ T cells. (B) Proportion of activated ci...
<p>The samples were collected from SIT-untreated AR patients (open circles), SIT-treated AR patients...
<p>(A) Comparison of the ability of healthy donors and CHB patients to produce IFN-α. PBMCs (2×10<su...
<p>IGRAs: Interferon-γ release assays; QFT-GIT: QuantiFERON®-TB Gold In-Tube; n/N: positive cases/ca...
<p>(A) CD4<sup>+</sup> and CD8<sup>+</sup>T cell numbers are significant decreased in the peripheral...
<p>(A-B) Comparison of (A) the total magnitudes (<i>y axis</i>) of <i>ex vivo</i> ELISPOT IFN-γ T-ce...